UK migraine study tracks Real-World rimegepant relief

NCT ID NCT06898047

Ongoing Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 250 adults in the UK who already use rimegepant for migraine attacks. Over 12 weeks, they report how quickly the drug eases pain and other symptoms. The goal is to see how consistently rimegepant works in everyday life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rimegepant (oral lyophilisate)
What this could lead to: If successful, this study could confirm how reliably rimegepant works for acute migraine in real-world UK settings, supporting its use.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It only follows people already using the drug, so no new treatment is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Pfizer

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.